Predictors of Treatment Outcome for Smokers With and Without Schizophrenia
The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Rutgers, The State University of New Jersey.
Recruitment status was Active, not recruiting
Information provided by:
Rutgers, The State University of New Jersey
First received: July 11, 2007
Last updated: March 3, 2011
Last verified: March 2011
The primary purpose of this investigation is to determine the predictive value of task persistence as measured by a mirror tracing task. A secondary purpose is to evaluate differences in task persistence in smokers with or without schizophrenia. It is hypothesized that task persistence in smokers in both diagnostic categories (schizophrenia and no schizophrenia) will predict tobacco dependence treatment outcome at one and six months. It is also hypothesized that smokers with schizophrenia will show lower levels of task persistence after controlling for other motor skills than smokers without schizophrenia.
||Time Perspective: Prospective
||Predictors of Treatment Outcome for Smokers With and Without Schizophrenia
Primary Outcome Measures:
- Abstinence from cigarettes. [ Time Frame: Follow up at 1-month and 6-months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Days until relapse [ Time Frame: 1-month and 6-month follow up ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
Please see brief summary above.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Individuals from mental health centers in Central New Jersey or non-psychiatric controls from the community
- Current smokers must be over the age of 18,
- Must fit into the diagnostic groups schizophrenia / schizoaffective disorder; or the non-schizophrenia group.
- Must smoke at least 10 cigarettes per day
- Must be capable of giving informed consent as measured by Folstein Mini Mental Status Exam of at least 22.
- Those unable to give informed consent.
- Psychotic disorders other than schizophrenia
Please refer to this study by its ClinicalTrials.gov identifier: NCT00501007
|UMDNJ Tobacco Dependence Clinic
|New Brunswick, New Jersey, United States, 08901 |
University of Medicine and Dentistry New Jersey
||Marc L. Steinberg, PH.D
||Rutgers, The State University of New Jersey
No publications provided
||Marc L. Steinberg, Ph.D., Assistant Professor, Robert Wood Johnson Medical School - UMDNJ
History of Changes
|Other Study ID Numbers:
||K23 DA018203, K23DA018203
|Study First Received:
||July 11, 2007
||March 3, 2011
||United States: Federal Government
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 05, 2013
Tobacco Use Disorder
Schizophrenia and Disorders with Psychotic Features